LifeMD (LFMD)
Connecting patients to virtual primary and specialty care with pharmacy access.
Something off on this page? Send us feedback.
Combines subscription-led virtual primary and specialty care with affiliated providers and pharmacy access for patients across the United States.
Provides direct-to-patient virtual care across primary and specialty needs, including urgent and chronic care, men’s and women’s health, hormone health, weight management, insomnia, dermatology, and cardiology. Clinically appropriate prescription and over-the-counter treatments sit alongside telemedicine, laboratory, and pharmacy access.
Built on a subscription-led model, the platform connects patients with affiliated clinical providers and pharmacy services throughout the United States. The women’s-health expansion came through the OHHMD asset acquisition, while the WorkSimpli sale left virtual care and pharmacy as the continuing business. Delivery depends on the digital-care platform, affiliated providers, pharmacy capability, laboratory access, and a US patient-care center.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 18, 2026 | H.C. Wainwright | Target | Target: $10 | Target: $9 |
| Aug 7, 2026 | KeyBanc | Reiterate | Rating: —Target: $8 | Target: $5 |
| Aug 6, 2026 | Lake Street | Target | Target: $18 | Target: $5 |
| Aug 6, 2026 | Mizuho Securities | Target | Target: $6 | Target: $7 |
| Aug 6, 2026 | BTIG | Reiterate | Rating: —Target: $10 | Target: $9 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $25.1M · Total debt $6.0M · Total assets $59.9M · Shareholders' equity $8.0M
- Revenue
- $47.3M
- Operating income
- −$7.1M
- Net income
- −$7.1M
No dividends on record.
| Institutions | 45.11% | 21.74M shares | |
|---|---|---|---|
| 124 holders · as of Jun 30, 2026 | |||
| Insiders | 9.80% | 4.72M shares | |
| 18 holders · as of Aug 18, 2026 | |||
| Other | 45.09% | 21.74M shares | |
| remainder | |||
48.20M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 6.30% | 3.03M | as of Jun 30, 2026 |
Federated Hermes, Inc.Institution | 5.70% | 2.75M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 3.60% | 1.73M | as of Jun 30, 2026 |
State Street CorpInstitution | 2.74% | 1.32M | as of Jun 30, 2026 |
Renaissance Technologies LLCInstitution | 2.24% | 1.08M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Dec 9, 2025 | Jessica Friedeman | officer: Chief Marketing Officer | −15,000 | $3.61 |
- Hims & Hers Health
Subscription telehealth and prescriptions across overlapping specialties
- Teladoc Health
Virtual primary and specialty care across acute and chronic needs
- Amazon
One Medical virtual primary care and pharmacy-integrated GLP-1 care
- Amwell
Hybrid virtual primary, urgent, and specialty care platform
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| LifeMD | $3.28 | +1.71% | $156.0M | — | — | 0.8 | −24.0% |
| Hims & Hers Health | $31.47 | +7.22% | $6.55B | — | 146.3 | 2.5 | +38.3% |
| Teladoc Health | $6.27 | −0.08% | $1.14B | — | — | 0.5 | −4.0% |
| Amazon | $254.85 | −1.39% | $2.78T | 20.8 | 27.3 | 3.6 | +19.6% |
| Amwell | $13.35 | −0.52% | $228.3M | — | — | 1.0 | −26.6% |
| Median | 20.8 | 86.8 | 1.8 | +7.8% |